Tarsus Pharmaceuticals Inc • TARS

Capital at risk.

About Tarsus Pharmaceuticals Inc
Ticker
info
TARS
Trading on
info
NASDAQ
ISIN
info
US87650L1035
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Bobak R. Azamian M.D.
Headquarters
info
15440 Laguna Canyon Road, Irvine, CA, United States, 92618
Employees
info
323
Website
info
tarsusrx.com
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Metrics
BasicAdvanced
Market cap
info
$1.71B
P/E ratio
info
-
EPS
info
-$2.70
Dividend Yield
info
0.00%
Beta
info
0.84
Forward P/E ratio
info
0
EBIDTA
info
$-108M
Ex dividend date
info
-
Price & volume
Market cap
info
$1.71B
Average daily volume
info
0.6M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
7.31
Price to book
info
4.98
Earnings
EPS
info
-$2.70
EPS estimate (current quarter)
info
-$0.63
EPS estimate (next quarter)
info
-$0.29
EBITDA
info
$-108M
Revenues (TTM)
info
$234M
Revenues per share (TTM)
info
$6.05
Technicals
Beta
info
0.84
52-week High
info
$57.28
52-week Low
info
$20.08
50-day moving average
info
$45.15
200-day moving average
info
$45.27
Short ratio
info
11.66
Short %
info
19.87%
Management effectiveness
ROE (TTM)
info
-33.98%
ROA (TTM)
info
-16.05%
Profit margin
info
-44.91%
Gross profit margin
info
$162M
Operating margin
info
-33.55%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
183.70%
Share stats
Outstanding Shares
info
42M
Float
info
32.7M
Insiders %
info
3.25%
Institutions %
info
110.77%
Analyst Insights & forecasts
info

88% Buy

12% Hold

0% Sell

Based on information from 8 analysts.

Average price target

info
$74.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.88
-$0.92
4.35%
Q2 • 24Beat
-$0.61
-$0.94
35.11%
Q3 • 24Beat
-$0.60
-$0.82
26.44%
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$66.4M
$-23.1M
-34.80%
Q4 • 24
$78.3M
$-25.1M
-32.07%
Q1 • 25
17.96%
8.68%
-7.86%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$377M
$152M
40.44%
Q4 • 24
$501M
$158M
31.61%
Q1 • 25
32.83%
3.83%
-21.83%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-22.2M
$-59.6M
$2.9M
$-27.3M
Q4 • 24
$-20.7M
$-34.9M
$137M
$-21.2M
Q1 • 25
-6.90%
-41.35%
4,565.60%
-22.06%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Tarsus Pharmaceuticals Inc share?
Collapse

Tarsus Pharmaceuticals Inc shares are currently traded for undefined per share.

How many shares does Tarsus Pharmaceuticals Inc have?
Collapse

Tarsus Pharmaceuticals Inc currently has 42M shares.

Does Tarsus Pharmaceuticals Inc pay dividends?
Collapse

No, Tarsus Pharmaceuticals Inc doesn't pay dividends.

What is Tarsus Pharmaceuticals Inc 52 week high?
Collapse

Tarsus Pharmaceuticals Inc 52 week high is $57.28.

What is Tarsus Pharmaceuticals Inc 52 week low?
Collapse

Tarsus Pharmaceuticals Inc 52 week low is $20.08.

What is the 200-day moving average of Tarsus Pharmaceuticals Inc?
Collapse

Tarsus Pharmaceuticals Inc 200-day moving average is $45.27.

Who is Tarsus Pharmaceuticals Inc CEO?
Collapse

The CEO of Tarsus Pharmaceuticals Inc is Dr. Bobak R. Azamian M.D..

How many employees Tarsus Pharmaceuticals Inc has?
Collapse

Tarsus Pharmaceuticals Inc has 323 employees.

What is the market cap of Tarsus Pharmaceuticals Inc?
Collapse

The market cap of Tarsus Pharmaceuticals Inc is $1.71B.

What is the P/E of Tarsus Pharmaceuticals Inc?
Collapse

The current P/E of Tarsus Pharmaceuticals Inc is null.

What is the EPS of Tarsus Pharmaceuticals Inc?
Collapse

The EPS of Tarsus Pharmaceuticals Inc is -$2.70.

What is the PEG Ratio of Tarsus Pharmaceuticals Inc?
Collapse

The PEG Ratio of Tarsus Pharmaceuticals Inc is null.

What do analysts say about Tarsus Pharmaceuticals Inc?
Collapse

According to the analysts Tarsus Pharmaceuticals Inc is considered a buy.